Characteristics of 6 patients with CML after SCT
. | Time from SCT to analysis . | Disease stage at SCT . | Treatment before SCT . | Type of SCT . | DLI interval to analysis . | Disease status at analysis . | . | T-cell response . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UPN . | . | . | . | . | . | . | GVHD . | PR1 . | WT1 . | BCR-ABL . | ||
| 181 | 36 mo | CML-CP | HU | HLA-id | 18 mo | MRD | Acute I-skin, chronic-skin limited | Y | Y | Y | ||
| 210 | 180 d | CML, 2nd CP | HU, IFN-α, hyper CVAD, 3 cycles | HLA-id | N | CR | Chronic-skin limited | Y | Y | N | ||
| 223 | 35 mo | CML-CP | HU, IFN-α | HLA-id | 27 mo | CR | Acute I-liver | N | N | Y | ||
| 283 | 23 mo | CML-MBC, 2nd CP | Imatinib mesylate | HLA-id | 20 mo | CR | Acute II-skin, chronic skin-extensive | N | N | N | ||
| 319 | 100 d | CML-CP | HU, anagrelide | HLA-id | 55 d | MRD | Acute I-skin, chronic skin | Y | Y | Y | ||
| 327 | 100 d | CML-CP | HU, Ara-C | HLA-id | 55 d | MRD | None | N | Y | Y | ||
. | Time from SCT to analysis . | Disease stage at SCT . | Treatment before SCT . | Type of SCT . | DLI interval to analysis . | Disease status at analysis . | . | T-cell response . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UPN . | . | . | . | . | . | . | GVHD . | PR1 . | WT1 . | BCR-ABL . | ||
| 181 | 36 mo | CML-CP | HU | HLA-id | 18 mo | MRD | Acute I-skin, chronic-skin limited | Y | Y | Y | ||
| 210 | 180 d | CML, 2nd CP | HU, IFN-α, hyper CVAD, 3 cycles | HLA-id | N | CR | Chronic-skin limited | Y | Y | N | ||
| 223 | 35 mo | CML-CP | HU, IFN-α | HLA-id | 27 mo | CR | Acute I-liver | N | N | Y | ||
| 283 | 23 mo | CML-MBC, 2nd CP | Imatinib mesylate | HLA-id | 20 mo | CR | Acute II-skin, chronic skin-extensive | N | N | N | ||
| 319 | 100 d | CML-CP | HU, anagrelide | HLA-id | 55 d | MRD | Acute I-skin, chronic skin | Y | Y | Y | ||
| 327 | 100 d | CML-CP | HU, Ara-C | HLA-id | 55 d | MRD | None | N | Y | Y | ||
UPN indicates unique patient number; DLI, donor lymphocyte infusion; GVHD, graft-versus-host disease; CML-CP, CML chronic phase; HU, hydroxyurea; HLA-id, HLA identical sibling transplantation; N, no DLI given; MRD, minimal residue disease BCR-ABL+ by RT-PCR; IFN-α, interferon-α; hyper CVAD, cyclophosphamide, doxorubicin, vincristine, and dexamethasone; CR, molecular remission; CML-MBC, CML myeloid blast crisis; and Ara-C, cytosine-arabinoside.